Dermatology And Therapy SCIE

國際簡稱：DERMATOLOGY THER 參考譯名：皮膚科和治療

主要研究方向：Medicine-Dermatology 非預(yù)警期刊審稿周期： 6 Weeks

《皮膚科和治療》(Dermatology And Therapy)是一本由Springer Healthcare出版的以Medicine-Dermatology為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預(yù)警名單。

3區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
187 年發(fā)文量
3.5 IF影響因子
開放是否OA
2011 創(chuàng)刊年份
12 issues per year 出版周期
English 出版語言

Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.

Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.

The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.

[ 查看全部 ]

投稿咨詢加急咨詢

Dermatology And Therapy期刊信息

ISSN：2193-8210
出版語言：English
是否OA：開放
E-ISSN：2190-9172
出版地區(qū)：Germany
是否預(yù)警：否
出版商：Springer Healthcare
出版周期：12 issues per year
創(chuàng)刊時(shí)間：2011
開源占比：0.992
Gold OA文章占比：98.75%
OA被引用占比：1
出版國人文章占比：0.04
出版撤稿占比：0
研究類文章占比：75.94%

Dermatology And Therapy CiteScore評價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

1.424

1.328

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Dermatology	Q1	17 / 142	88%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會(huì)議論文、書籍章節(jié)和數(shù)據(jù)論文。

Dermatology And Therapy中科院評價(jià)數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	DERMATOLOGY 皮膚病學(xué)	3區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	DERMATOLOGY 皮膚病學(xué)	2區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	DERMATOLOGY 皮膚病學(xué)	3區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	DERMATOLOGY 皮膚病學(xué)	3區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	DERMATOLOGY 皮膚病學(xué)	3區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	DERMATOLOGY 皮膚病學(xué)	3區(qū)

Dermatology And Therapy JCR評價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：DERMATOLOGY	SCIE	Q1	20 / 94	79.3%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：DERMATOLOGY	SCIE	Q1	19 / 94	80.32%

Dermatology And Therapy歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Dermatology And Therapy中國學(xué)者發(fā)文選摘

1、Design of Effisayil (TM) 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis
Author: Morita, Akimichi; Choon, Siew Eng; Bachelez, Herve; Anadkat, Milan J.; Marrakchi, Slaheddine; Zheng, Min; Tsai, Tsen-Fang; Turki, Hamida; Hua, Harry; Rajeswari, Sushmita; Thoma, Christian; Burden, A. David

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 1, pp. 347-359. DOI: 10.1007/s13555-022-00835-6
2、Effect of 30% Supramolecular Salicylic Acid Peel on Skin Microbiota and Inflammation in Patients with Moderate-to-Severe Acne Vulgaris
Author: Shao, Xinyi; Chen, Yangmei; Zhang, Lingzhao; Zhang, Yujie; Ariyawati, Asoka; Chen, Tingqiao; Chen, Jiayi; Liu, Lin; Pu, Yihuan; Li, Yuxin; Chen, Jin

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 1, pp. 155-168. DOI: 10.1007/s13555-022-00844-5
3、Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
Author: Yu, Chen; Wang, Gang; Burge, Russel T.; Ye, Erjia; Dou, Guanshen; Li, Jinnan; Harrison, Ryan W.; McLean, Robert R.; Kerti, Samantha J.; Bagel, Jerry

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 1, pp. 187-206. DOI: 10.1007/s13555-022-00843-6
4、Application of Comfort Therapy under eCASH Concept in Acute and Chronic Wound Treatment
Author: Shi, Shuting; Wei, Jiayu; Lyu, Guozhong; Zhong, Xiaohui; Zhu, Lihong; Yang, Minlie

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 1, pp. 299-314. DOI: 10.1007/s13555-022-00852-5
5、Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China
Author: Yang, Jing; Hu, Kun; Li, Xingyu; Hu, Jingjin; Tan, Minjia; Zhang, Mi; Kuang, Yehong; Lv, Chengzhi; Chen, Junchen

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 2, pp. 477-485. DOI: 10.1007/s13555-022-00869-w
6、Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study
Author: Jiang, Congjun; Zhou, Huan; Zhang, Wanlu; Xia, Yu; Li, Baiyong; Ni, Xiang; Wang, Guoqin; Zhang, Wenhui; Chen, Benchao; He, Zhimei; Zhang, Min; Chen, Rui; Jin, Hongzhong; Deng, Liehua

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 2, pp. 555-567. DOI: 10.1007/s13555-022-00880-1
7、An Intelligent Diagnostic Model for Melasma Based on Deep Learning and Multimode Image Input
Author: Liu, Lin; Liang, Chen; Xue, Yuzhou; Chen, Tingqiao; Chen, Yangmei; Lan, Yufan; Wen, Jiamei; Shao, Xinyi; Chen, Jin

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 2, pp. 569-579. DOI: 10.1007/s13555-022-00874-z
8、Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective
Author: Chu, Chia-Yu; Yao, Tsung-Chieh; Shih, I. -Hsin; Yang, Chin-Yi; Chin, Chan Lee; Ibrahim, Sabeera Begum Binti Kader; Thevarajah, Suganthi; Fon, Leong Kin; Ho, Marco Hok-Kung; Mo, Chow Chung; Yu, Chow Pok; Loo, Steven King-Fan; Luger, Thomas

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 3, pp. 717-727. DOI: 10.1007/s13555-022-00886-9